P132: Clinical characteristics and management of patients with mucopolysaccharidosis II (MPS II) in the United States from the Hunter Outcome Survey*
Barbara Burton,
Can Ficicioglu,
Helio Pedro,
Ravi Pathak,
Ian Robinson,
Ekaterina Wright,
Joseph Muenzer
Affiliations
Barbara Burton
Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL
Can Ficicioglu
Division of Human Genetics and Metabolism, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Helio Pedro
Center for Genetic and Genomic Medicine, Hackensack University Medical Center, Hackensack, NJ
Ravi Pathak
Takeda Pharmaceuticals USA Inc., Lexington, MA
Ian Robinson
Takeda Pharmaceuticals USA Inc., Lexington, MA
Ekaterina Wright
Takeda Pharmaceuticals USA Inc., Lexington, MA
Joseph Muenzer
University of North Carolina at Chapel Hill, Chapel Hill, NC
